{"Title": "Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial", "Year": 2020, "Source": "Gynecol. Oncol.", "Volume": "159", "Issue": 2, "Art.No": null, "PageStart": 442, "PageEnd": 448, "CitedBy": 0, "DOI": "10.1016/j.ygyno.2020.09.006", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85091613887&origin=inward", "Abstract": "\u00a9 2020 The AuthorsObjective: Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in heavily pretreated patients and as maintenance treatment in patients with newly-diagnosed or recurrent ovarian cancer following a response to platinum-based chemotherapy. We present long-term safety data for niraparib from the ENGOT-OV16/NOVA trial. Methods: This multicenter, double-blind, randomized, controlled phase III trial evaluated the efficacy and safety of niraparib for the treatment of recurrent ovarian cancer. Patients were randomly assigned 2:1 to receive either once-daily niraparib 300 mg or placebo. Two independent cohorts were enrolled based on germline BRCA mutation status. The primary endpoint was progression-free survival, reported previously. Long-term safety data were from the most recent data cutoff (September 2017). Results: Overall, 367 patients received niraparib 300 mg once daily. Dose reductions due to TEAEs were highest in month 1 (34%) and declined every month thereafter. Incidence of any-grade and grade \u2265 3 hematologic and symptomatic TEAEs was also highest in month 1 and subsequently declined. Incidence of grade \u2265 3 thrombocytopenia decreased from 28% (month 1) to 9% and 5% (months 2 and 3, respectively), with protocol-directed dose interruptions and/or reductions. Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) were reported in 2 and 6 niraparib-treated patients, respectively, and in 1 placebo patient each. Treatment discontinuations due to TEAEs were <5% in each month and time interval measured. Conclusion: These data demonstrate the importance of appropriate dose reduction according to toxicity criteria and support the safe long-term use of niraparib for maintenance treatment in patients with recurrent ovarian cancer. Trial registration: ClinicalTrials.gov identifier: NCT01847274.", "AuthorKeywords": ["Gynecologic oncology", "Long-term safety", "Niraparib", "Ovarian cancer", "Poly(ADP ribose) polymerase inhibitor"], "IndexKeywords": null, "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85091613887", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Obstetrics and Gynecology", "MEDI", "2729"]], "AuthorData": {"7102855234": {"Name": "Mirza M.R.", "AuthorID": "7102855234", "AffiliationID": "60006564, 60015199", "AffiliationName": "Nordic Society of Gynaecological Oncology Clinical Trial Unit (NSGO-CTU), Rigshospitalet\u2013Copenhagen University Hospital"}, "6603264476": {"Name": "Benigno B.", "AuthorID": "6603264476", "AffiliationID": "60030845", "AffiliationName": "Northside Hospital"}, "57192185947": {"Name": "D\u00f8rum A.", "AuthorID": "57192185947", "AffiliationID": "60026108, 60105037", "AffiliationName": "Radiumhospitalet, Oslo University Hospital, NSGO"}, "24401399500": {"Name": "Mahner S.", "AuthorID": "24401399500", "AffiliationID": "60000291, 60028717", "AffiliationName": "Department of Obstetrics and Gynecology, University Hospital, LMU Munich, AGO"}, "8853710000": {"Name": "Bessette P.", "AuthorID": "8853710000", "AffiliationID": "60011832", "AffiliationName": "Sherbrooke University"}, "57200994644": {"Name": "Barcel\u00f3 I.B.", "AuthorID": "57200994644", "AffiliationID": "60068628", "AffiliationName": "Hospital Son Ll\u00e0tzer, GEICO"}, "8587762200": {"Name": "Berton-Rigaud D.", "AuthorID": "8587762200", "AffiliationID": "60019528", "AffiliationName": "Institut de Canc\u00e9rologie de l'Ouest Centre Ren\u00e9 Gauducheau, GINECO"}, "7007134127": {"Name": "Ledermann J.A.", "AuthorID": "7007134127", "AffiliationID": "60109234, 60022148", "AffiliationName": "UCL Cancer Institute, University College London, NCRI"}, "6505912311": {"Name": "Rimel B.J.", "AuthorID": "6505912311", "AffiliationID": "60016173", "AffiliationName": "Cedars-Sinai Medical Center"}, "56265618500": {"Name": "Herrstedt J.", "AuthorID": "56265618500", "AffiliationID": "60136205", "AffiliationName": "Zealand University Hospital, NSGO"}, "8948084200": {"Name": "Lau S.", "AuthorID": "8948084200", "AffiliationID": "60002494", "AffiliationName": "McGill University"}, "57217863422": {"Name": "du Bois A.", "AuthorID": "57217863422", "AffiliationID": "60002468", "AffiliationName": "Kliniken Essen Mitte, AGO"}, "24587557900": {"Name": "Herr\u00e1ez A.C.", "AuthorID": "24587557900", "AffiliationID": "60032461", "AffiliationName": "Hospital Cl\u00ednico San Carlos, GEICO"}, "37037660200": {"Name": "Kalbacher E.", "AuthorID": "37037660200", "AffiliationID": "60027466", "AffiliationName": "Centre Hospitalier R\u00e9gional et Universitaire de Besan\u00e7on, GINECO"}, "6601968581": {"Name": "Buscema J.", "AuthorID": "6601968581", "AffiliationID": "60020398", "AffiliationName": "Arizona Oncology Associates"}, "57192342135": {"Name": "Lorusso D.", "AuthorID": "57192342135", "AffiliationID": "60006583, 60073799", "AffiliationName": "Fondazione Policlinico Universitario a Gemelli IRCCS, Istituto Nazionale dei Tumori, MITO"}, "56998909400": {"Name": "Vergote I.", "AuthorID": "56998909400", "AffiliationID": "60025063, 60121262", "AffiliationName": "University of Leuven, Leuven Cancer Institute, BGOG"}, "7005868550": {"Name": "Levy T.", "AuthorID": "7005868550", "AffiliationID": "60029655", "AffiliationName": "Wolfson Medical Center, ISGO"}, "57219186991": {"Name": "Wang P.", "AuthorID": "57219186991", "AffiliationID": "60097308", "AffiliationName": "GlaxoSmithKline"}, "57212538935": {"Name": "Gupta D.", "AuthorID": "57212538935", "AffiliationID": "60097308", "AffiliationName": "GlaxoSmithKline"}, "57219187842": {"Name": "de Jong F.A.", "AuthorID": "57219187842", "AffiliationID": "60111461", "AffiliationName": "GlaxoSmithKline"}, "6701616188": {"Name": "Matulonis U.A.", "AuthorID": "6701616188", "AffiliationID": "60014334", "AffiliationName": "Dana-Farber Cancer Institute"}}}